sage-sch13g_17761.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
 
(Amendment No. __)*
 
 

Sage Therapeutics, Inc.
(Name of Issuer)
 
 
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
 
 
78667J108
(CUSIP Number)
 

December 31, 2014
(Date of Event which Requires Filing of this Statement)
 
 
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨  Rule 13d-1(b)
o  Rule 13d-1(c)
x Rule 13d-1(d)
 
 
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
 
 
CUSIP No. 78667J108
13G
Page 2 of 12
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Third Rock Ventures II, L.P.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
(b) o
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware limited partnership
NUMBER OF
5
SOLE VOTING POWER
 
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
 
11,681,008
EACH
REPORTING
PERSON
7
SOLE DISPOSITIVE POWER
 
0
WITH
8
SHARED DISPOSITIVE POWER
 
11,681,008
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
11,681,008
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)     o
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
45.3%
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
PN
 
 
 
 
CUSIP No. 78667J108
13G
Page 3 of 12
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Third Rock Ventures GP II, L.P.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
(b) o
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware limited partnership
NUMBER OF
5
SOLE VOTING POWER
 
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
 
11,681,008
EACH
REPORTING
PERSON
7
SOLE DISPOSITIVE POWER
 
0
WITH
8
SHARED DISPOSITIVE POWER
 
11,681,008
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
11,681,008
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
45.3%
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
PN
 
 
 
 
CUSIP No. 78667J108
13G
Page 4 of 12
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
TRV GP II, LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
(b) o
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware limited liability company
NUMBER OF
5
SOLE VOTING POWER
 
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
 
11,681,008
EACH
REPORTING
PERSON
7
SOLE DISPOSITIVE POWER
 
0
WITH
8
SHARED DISPOSITIVE POWER
 
11,681,008
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
11,681,008
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
45.3%
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
OO
 
 
 
 
 
CUSIP No. 78667J108
13G
Page 5 of 12
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Mark Levin
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
(b) o
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
NUMBER OF
5
SOLE VOTING POWER
 
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
 
11,681,008
EACH
REPORTING
PERSON
7
SOLE DISPOSITIVE POWER
 
0
WITH
8
SHARED DISPOSITIVE POWER
 
11,681,008
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
11,681,008
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
45.3%
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
IN
 
 
 
 
CUSIP No. 78667J108
13G
Page 6 of 12
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Kevin P. Starr
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
(b) o
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
NUMBER OF
5
SOLE VOTING POWER
 
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
 
11,681,008
EACH
REPORTING
PERSON
7
SOLE DISPOSITIVE POWER
 
0
WITH
8
SHARED DISPOSITIVE POWER
 
11,681,008
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
11,681,008
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
45.3%
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
IN
 
 
 
 
CUSIP No. 78667J108
13G
Page 7 of 12
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Robert I. Tepper
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) o
(b) o
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
NUMBER OF
5
SOLE VOTING POWER
 
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
 
11,681,008
EACH
REPORTING
PERSON
7
SOLE DISPOSITIVE POWER
 
0
WITH
8
SHARED DISPOSITIVE POWER
 
11,681,008
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
11,681,008
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
45.3%
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
IN
 
 
 
CUSIP No. 78667J108
13G
Page 8 of 12
 
 
Item 1(a).               Name of Issuer:

Sage Therapeutics, Inc.
 
 
Item 1(b).               Address of Issuer’s Principal Executive Offices:

215 First Street, Cambridge, MA 02142.

 
Item 2(a).               Names of Persons Filing:

This statement is being filed by Third Rock Ventures II, L.P. (“TRV II”); Third Rock Ventures GP II, L.P. (“TRV GP II”), which is the sole general partner of TRV II; TRV GP II, LLC (“TRV GP II LLC”), which is the sole general partner of TRV GP II; and Mark Levin (“Levin”), Kevin Starr (“Starr”), and Robert Tepper (“Tepper”), each a managing member of TRV GP II LLC.  TRV II, TRV GP II, TRV GP II LLC, Levin, Starr, and Tepper are sometimes referred to collectively herein as the “Reporting Persons”.
 
 
Item 2(b).               Address of Principal Business Office or, if none, Residence:
 
The address of the principal business office of each Reporting Person is Third Rock Ventures, LLC, 29 Newbury Street, 3rd Floor, Boston, MA 02116.
 
 
Item 2(c).               Citizenship:

Each of TRV II and TRV GP II is a Delaware limited partnership.  TRV GP II LLC is a Delaware limited liability company.  Levin, Tepper, and Starr are United States citizens.
 
 
Item 2(d).              Title of Class of Securities:
 
Common Stock, $0.0001 par value (“Common Stock”).
 
 
Item 2(e).               CUSIP Number:

78667J108.
 
 
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.
 
 
Item 4.                    Ownership.

(a)    
Amount Beneficially Owned: TRV II is the record owner of 11,681,008 shares of Common Stock as of December 31, 2014 (the “Shares”).  As the sole general partner of TRV II, TRV GP II may be deemed to own beneficially the Shares.  As the sole general partner of TRV GP II, TRV GP II LLC likewise may be deemed to own beneficially the Shares.  As managing members of TRV GP II LLC, each of Levin, Starr, and Tepper also may be deemed to own beneficially the Shares.
 
 
 
 
 
CUSIP No. 78667J108
13G
Page 9 of 12
 
 
 
(b)    
Percent of Class:  See Line 11 of cover sheets.  The percentages set forth on the cover sheet for each Reporting Person are calculated based on 25,792,623 shares of Common Stock reported by the Issuer to be outstanding as of November 1, 2014 on Form 10-Q as filed with the Securities and Exchange Commission on November 13, 2014.
 
(c)     
Number of shares as to which such person has:

 
(i)
sole power to vote or to direct the vote:  See Line 5 of cover sheets.
     
 
(ii)
shared power to vote or to direct the vote:  See Line 6 of cover sheets.
     
 
(iii)
sole power to dispose or to direct the disposition of:  See Line 7 of cover sheets.
     
 
(iv)
shared power to dispose or to direct the disposition of: See Line 8 of cover sheets.
     
 
Each Reporting Person disclaims beneficial ownership of such Securities except for the shares, if any, such Reporting Person holds of record.

 
Item 5.                   Ownership of Five Percent or Less of a Class.

Not applicable.

 
Item 6.                   Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.
 

Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

 
Item 8.                   Identification and Classification of Members of the Group.

Not applicable.  The Reporting Persons expressly disclaim membership in a “group” as used in Rule 13d-5(b).

 
Item 9.                   Notice of Dissolution of Group.

Not applicable.

 
Item 10.                 Certification.

Not applicable.  This Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d–1(c).
 
 
 
Material to be Filed as Exhibits.

Exhibit 1 – Agreement regarding filing of joint Schedule 13G.

Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.
 
 
 
CUSIP No. 78667J108
13G
Page 10 of 12
 
 
SIGNATURE
 
 
After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date:       February 13, 2015


THIRD ROCK VENTURES II, L.P.

By:
THIRD ROCK VENTURES GP II, L.P.
 
General Partner

 
By:
TRV GP II, LLC
General Partner

By:                         *                                
Kevin Gillis
Chief Financial Officer


THIRD ROCK VENTURES GP II, L.P.

By:
TRV GP II, LLC
General Partner

By:                               *                           
Kevin Gillis
Chief Financial Officer


TRV GP II, LLC

By:                               *                              
Kevin Gillis
Chief Financial Officer


                 *                                                  
 
Mark Levin
 

                 *                                                  
 
Kevin P. Starr


                 *                                                  
 
Robert I. Tepper

 
*By:  /s/ Kevin Gillis                               
          Kevin Gillis
          As attorney-in-fact
 

This Schedule 13G was executed by Kevin Gillis on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.
 
 
 
CUSIP No. 78667J108
13G
Page 11 of 12
 
EXHIBIT 1

AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Sage Therapeutics, Inc.
 
EXECUTED this 13th day of February, 2015.
 
 
THIRD ROCK VENTURES II, L.P.

By:
THIRD ROCK VENTURES GP II, L.P.
 
General Partner

 
By:
TRV GP II, LLC
General Partner

By:                         *                                
Kevin Gillis
Chief Financial Officer


THIRD ROCK VENTURES GP II, L.P.

By:
TRV GP II, LLC
General Partner

By:                               *                           
Kevin Gillis
Chief Financial Officer


TRV GP II, LLC

By:                               *                              
Kevin Gillis
Chief Financial Officer


                 *                                                  
 
Mark Levin
 

                 *                                                  
 
Kevin P. Starr

                 *                                                  
 
Robert I. Tepper



*By:  /s/ Kevin Gillis                               
          Kevin Gillis
          As attorney-in-fact
 
 
 
This Agreement was executed by Kevin Gillis on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.
 
 
 
CUSIP No. 78667J108
13G
Page 12 of 12
 
EXHIBIT 2

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer, member or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 16th day of January, 2014.


/s/ Mark Levin                      
Mark Levin


/s/ Kevin P. Starr                  
Kevin P. Starr


/s/ Robert I. Tepper              
Robert I. Tepper